Isoliensinine Attenuates Renal Fibrosis and Inhibits TGF-β1/Smad2/3 Signaling Pathway in Spontaneously Hypertensive Rats

References

• Stompór T, Perkowska-Ptasińska A. Hypertensive kidney disease: a true epidemic or rare disease? Pol Arch Intern Med. 2020;130(2):130–139. doi:10.20452/pamw.15150
   PubMedGoogle Scholar
• Saran R, Robinson B, Abbott KC, et al. US renal data system 2019 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2020;75(Suppl 1):A6–A7. doi:10.1053/j.ajkd.2019.09.003
   PubMedGoogle Scholar
• Gusev E, Solomatina L, Zhuravleva Y, Sarapultsev A. The pathogenesis of end-stage renal disease from the standpoint of the theory of general pathological processes of inflammation. Int J Mol Sci. 2021;22(21). doi:10.3390/ijms222111453
   Web of Science ®Google Scholar
• Liu F, Zhuang S. New therapies for the treatment of renal fibrosis. Adv Exp Med Biol. 2019;1165:625–659. doi:10.1007/978-981-13-8871-2_31
   PubMed Web of Science ®Google Scholar
• Mennuni S, Rubattu S, Pierelli G, Tocci G, Fofi C, Volpe M. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. J Hum Hypertens. 2014;28(2):74–79. doi:10.1038/jhh.2013.55
   PubMed Web of Science ®Google Scholar
• Son M, Oh S, Choi J, Jang JT, Son KH, Byun K. Attenuating effects of dieckol on hypertensive nephropathy in spontaneously hypertensive rats. Int J Mol Sci. 2021;22(8). doi:10.3390/ijms22084230
   Web of Science ®Google Scholar
• Gu D, Fang D, Zhang M, et al. Gastrin, via activation of PPARα, protects the kidney against hypertensive injury. Clin Sci. 2021;135(2):409–427. doi:10.1042/CS20201340
   Web of Science ®Google Scholar
• Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet. 2005;365(9456):331–340.
   PubMed Web of Science ®Google Scholar
• Chen X, Wei S-Y, J-S L, et al. Overexpression of heme oxygenase-1 prevents renal interstitial inflammation and fibrosis induced by unilateral ureter obstruction. PLoS One. 2016;11(1):e0147084. doi:10.1371/journal.pone.0147084
   PubMed Web of Science ®Google Scholar
• Zhu H, Wang X, Wang X, Liu B, Yuan Y, Zuo X. Curcumin attenuates inflammation and cell apoptosis through regulating NF-κB and JAK2/STAT3 signaling pathway against acute kidney injury. Cell Cycle. 2020;19(15):1941–1951. doi:10.1080/15384101.2020.1784599
   PubMed Web of Science ®Google Scholar
• Sun Y, Jin D, Zhang Z, et al. The critical role of the Hippo signaling pathway in kidney diseases. Front Pharmacol. 2022;13:988175. doi:10.3389/fphar.2022.988175
   PubMed Web of Science ®Google Scholar
• Zhang M, Chen Y, Yang M-J, et al. Celastrol attenuates renal injury in diabetic rats via MAPK/NF-κB pathway. Phytother Res. 2019;33(4):1191–1198. doi:10.1002/ptr.6314
   PubMed Web of Science ®Google Scholar
• Patel S, Tang J, Overstreet JM, et al. Rac-GTPase promotes fibrotic TGF-β1 signaling and chronic kidney disease via EGFR, p53, and Hippo/YAP/TAZ pathways. FASEB J. 2019;33(9):9797–9810. doi:10.1096/fj.201802489RR
   PubMed Web of Science ®Google Scholar
• Y-Y G, Liu X-S, Huang X-R, X-Q Y, Lan H-Y. TGF-β in renal fibrosis: triumphs and challenges. Future Med Chem. 2020;12(9):853–866. doi:10.4155/fmc-2020-0005
   PubMed Web of Science ®Google Scholar
• Yoshioka K, Takemura T, Murakami K, et al. Transforming growth factor-beta protein and mRNA in glomeruli in normal and diseased human kidneys. Lab Invest. 1993;68(2):154–163.
   PubMed Web of Science ®Google Scholar
• Isaka Y. Targeting TGF-β signaling in kidney fibrosis. Int J Mol Sci. 2018;19(9). doi:10.3390/ijms19092532
   Web of Science ®Google Scholar
• Inazaki K, Kanamaru Y, Kojima Y, et al. Smad3 deficiency attenuates renal fibrosis, inflammation, and apoptosis after unilateral ureteral obstruction. Kidney Int. 2004;66(2):597–604.
   PubMed Web of Science ®Google Scholar
• Qin W, Chung ACK, Huang XR, et al. TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol. 2011;22(8):1462–1474. doi:10.1681/ASN.2010121308
   PubMed Web of Science ®Google Scholar
• Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest. 2003;112(10):1486–1494.
   PubMed Web of Science ®Google Scholar
• Peng D, Fu M, Wang M, Wei Y, Wei X. Targeting TGF-β signal transduction for fibrosis and cancer therapy. Mol Cancer. 2022;21(1):104. doi:10.1186/s12943-022-01569-x
   PubMed Web of Science ®Google Scholar
• Li X, Ding Z, Wu Z, Xu Y, Yao H, Lin K. Targeting the TGF-β signaling pathway for fibrosis therapy: a patent review (2015–2020). Expert Opin Ther Pat. 2021;31(8):723–743. doi:10.1080/13543776.2021.1896705
   PubMed Web of Science ®Google Scholar
• Lee S-Y, Kim SI, Choi ME. Therapeutic targets for treating fibrotic kidney diseases. Transl Res. 2015;165(4):512–530. doi:10.1016/j.trsl.2014.07.010
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–1769. doi:10.1016/S0140-6736(11)60405-4
   PubMed Web of Science ®Google Scholar
• Luangmonkong T, Suriguga S, Bigaeva E, et al. Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis. Br J Pharmacol. 2017;174(18):3107–3117. doi:10.1111/bph.13945
   PubMed Web of Science ®Google Scholar
• Zhu Y, Chai Y, Xiao G, et al. Astragalus and its formulas as a therapeutic option for fibrotic diseases: pharmacology and mechanisms. Front Pharmacol. 2022;13:1040350. doi:10.3389/fphar.2022.1040350
   PubMed Web of Science ®Google Scholar
• Qin T, Wu L, Hua Q, Song Z, Pan Y, Liu T. Prediction of the mechanisms of action of Shenkang in chronic kidney disease: a network pharmacology study and experimental validation. J Ethnopharmacol. 2020;246:112128. doi:10.1016/j.jep.2019.112128
   PubMed Web of Science ®Google Scholar
• Wang M, Chen D-Q, Chen L, et al. Novel inhibitors of the cellular renin-angiotensin system components, poricoic acids, target Smad3 phosphorylation and Wnt/β-catenin pathway against renal fibrosis. Br J Pharmacol. 2018;175(13):2689–2708. doi:10.1111/bph.14333
   PubMed Web of Science ®Google Scholar
• Arooj M, Imran S, Inam-Ur-Raheem M, et al. Lotus seeds (Nelumbinis semen) as an emerging therapeutic seed: a comprehensive review. Food Sci Nutr. 2021;9(7):3971–3987. doi:10.1002/fsn3.2313
   PubMed Web of Science ®Google Scholar
• Itoh A, Saitoh T, Tani K, et al. Bisbenzylisoquinoline Alkaloids from Nelumbo nucifera. Chem Pharm Bull. 2011;59(8):947–951.
   PubMed Web of Science ®Google Scholar
• Sharma BR, Gautam LNS, Adhikari D, Karki R. A comprehensive review on chemical profiling of Nelumbo nucifera: potential for drug development. Phytother Res. 2017;31(1). doi:10.1002/ptr.5732
   PubMed Web of Science ®Google Scholar
• Xie Y, Zhang Y, Zhang L-T, Zeng S-X, Guo Z-B, Zheng B-D. Protective effects of alkaloid compounds from Nelumbinis Plumula on tert-butyl hydroperoxide-induced oxidative stress. Molecules. 2013;18(9):10285–10300. doi:10.3390/molecules180910285
   PubMed Web of Science ®Google Scholar
• Liu Z, Hu L, Zhang Z, et al. Isoliensinine eliminates afterdepolarizations through inhibiting late sodium current and L-type calcium current. Cardiovasc Toxicol. 2021;21(1):67–78. doi:10.1007/s12012-020-09597-z
   PubMed Web of Science ®Google Scholar
• Qian J-Q. Cardiovascular pharmacological effects of bisbenzylisoquinoline alkaloid derivatives. Acta Pharmacol Sin. 2002;23(12):1086–1092.
   PubMed Web of Science ®Google Scholar
• Xiao JH, Zhang YL, Feng XL, Wang JL, Qian JQ. Effects of isoliensinine on angiotensin II-induced proliferation of porcine coronary arterial smooth muscle cells. J Asian Nat Prod Res. 2006;8(3):209–216.
   PubMed Web of Science ®Google Scholar
• Cheng Y, H-L L, Zhou Z-W, et al. Isoliensinine: a natural compound with “Drug-Like”. Potential Front Pharmacol. 2021;12:630385. doi:10.3389/fphar.2021.630385
   PubMed Web of Science ®Google Scholar
• Long L, Zhang X, Wen Y, et al. Qingda granule attenuates angiotensin ii-induced renal apoptosis and activation of the p53 pathway. Front Pharmacol. 2021;12:770863. doi:10.3389/fphar.2021.770863
   PubMed Web of Science ®Google Scholar
• Wu M, Wu X, Cheng Y, et al. Qingda granule attenuates angiotensin II-induced blood pressure and inhibits Ca2+/ERK signaling pathway. Front Pharmacol. 2021;12:688877. doi:10.3389/fphar.2021.688877
   PubMed Web of Science ®Google Scholar
• Li J, Ghazwani M, Zhang Y, et al. miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. J Hepatol. 2013;58(3):522–528. doi:10.1016/j.jhep.2012.11.011
   PubMed Web of Science ®Google Scholar
• Zhao T, Chen H, Cheng C, et al. Liraglutide protects high-glucose-stimulated fibroblasts by activating the CD36-JNK-AP1 pathway to downregulate P4HA1. Biomed Pharmacother. 2019;118:109224. doi:10.1016/j.biopha.2019.109224
   PubMed Web of Science ®Google Scholar
• Hwang I, Lee EJ, Park H, Moon D, Kim H-S. Retinol from hepatic stellate cells via STRA6 induces lipogenesis on hepatocytes during fibrosis. Cell Biosci. 2021;11(1):3. doi:10.1186/s13578-020-00509-w
   PubMed Web of Science ®Google Scholar
• Chen C-H, L-Y K, Chan H-C, et al. Electronegative low density lipoprotein induces renal apoptosis and fibrosis: STRA6 signaling involved. J Lipid Res. 2016;57(8):1435–1446. doi:10.1194/jlr.M067215
   PubMed Web of Science ®Google Scholar
• Nie W, Li M, Liu B, et al. A circular RNA, circPTPN14, increases MYC transcription by interacting with FUBP1 and exacerbates renal fibrosis. Cell Mol Life Sci. 2022;79(12):595. doi:10.1007/s00018-022-04603-9
   PubMed Web of Science ®Google Scholar
• Li J, Yang Y, Li Q, et al. STAT6 contributes to renal fibrosis by modulating PPARα-mediated tubular fatty acid oxidation. Cell Death Dis. 2022;13(1):66. doi:10.1038/s41419-022-04515-3
   PubMed Web of Science ®Google Scholar
• Yang Y, Li Q, Ling Y, et al. m6A eraser FTO modulates autophagy by targeting SQSTM1/P62 in the prevention of canagliflozin against renal fibrosis. Front Immunol. 2022;13:1094556. doi:10.3389/fimmu.2022.1094556
   PubMed Web of Science ®Google Scholar
• Sun X, Zhu M, Chen X, Jiang X. MYH9 inhibition suppresses TGF-β1-stimulated lung fibroblast-to-myofibroblast differentiation. Front Pharmacol. 2020;11:573524. doi:10.3389/fphar.2020.573524
   PubMed Web of Science ®Google Scholar
• Meng X-M, Nikolic-Paterson DJ, Lan HY. TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12(6):325–338. doi:10.1038/nrneph.2016.48
   PubMed Web of Science ®Google Scholar
• Geng X-Q, Ma A, J-Z H, et al. Ganoderic acid hinders renal fibrosis via suppressing the TGF-β/Smad and MAPK signaling pathways. Acta Pharmacol Sin. 2020;41(5):670–677. doi:10.1038/s41401-019-0324-7
   PubMed Web of Science ®Google Scholar
• Yao Y, Hu C, Song Q, et al. ADAMTS16 activates latent TGF-β, accentuating fibrosis and dysfunction of the pressure-overloaded heart. Cardiovasc Res. 2020;116(5):956–969. doi:10.1093/cvr/cvz187
   PubMed Web of Science ®Google Scholar
• Xiao H, Liao Y, Tang C, et al. RNA-Seq analysis of potential lncRNAs and genes for the anti-renal fibrotic effect of norcantharidin. J Cell Biochem. 2019;120(10):17354–17367. doi:10.1002/jcb.28999
   PubMed Web of Science ®Google Scholar
• Shen Y, Miao N, Xu J, et al. Metformin prevents renal fibrosis in mice with unilateral ureteral obstruction and inhibits Ang II-induced ECM production in renal fibroblasts. Int J Mol Sci. 2016;17(2). doi:10.3390/ijms17020146
   Web of Science ®Google Scholar
• Gupta G, Dahiya R, Singh Y, et al. Monotherapy of RAAS blockers and mobilization of aldosterone: a mechanistic perspective study in kidney disease. Chem Biol Interact. 2020;317:108975. doi:10.1016/j.cbi.2020.108975
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Aihara K-I, Sato T, et al. Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis. J Biol Chem. 2005;280(33):29661–29666.
   PubMed Web of Science ®Google Scholar
• Wong CKS, Falkenham A, Myers T, Légaré J-F. Connective tissue growth factor expression after angiotensin II exposure is dependent on transforming growth factor-β signaling via the canonical Smad-dependent pathway in hypertensive induced myocardial fibrosis. J Renin Angiotensin Aldosterone Syst. 2018;19(1):1470320318759358. doi:10.1177/1470320318759358
   Web of Science ®Google Scholar
• Wang N-P, Erskine J, Zhang -W-W, et al. Recruitment of macrophages from the spleen contributes to myocardial fibrosis and hypertension induced by angiotensin II. J Renin Angiotensin Aldosterone Syst. 2017;18(2):1470320317706653. doi:10.1177/1470320317706653
   Web of Science ®Google Scholar
• Watson S, Burnside T, Carver W. Angiotensin II-stimulated collagen gel contraction by heart fibroblasts: role of the AT1 receptor and tyrosine kinase activity. J Cell Physiol. 1998;177(2):224–231.
   PubMed Web of Science ®Google Scholar
• AlQudah M, Hale TM, Czubryt MP. Targeting the renin-angiotensin-aldosterone system in fibrosis. Matrix Biol. 2020;91–92. doi:10.1016/j.matbio.2020.04.005
   Web of Science ®Google Scholar
• Rockey DC, Bell PD, Hill JA. Fibrosis--a common pathway to organ injury and failure. N Engl J Med. 2015;372(12):1138–1149. doi:10.1056/NEJMra1300575
   PubMed Web of Science ®Google Scholar
• Zheng R, Zhu R, Li X, et al. N6-(2-Hydroxyethyl) adenosine from cordyceps cicadae ameliorates renal interstitial fibrosis and prevents inflammation via TGF-β1/Smad and NF-κB signaling pathway. Front Physiol. 2018;9:1229. doi:10.3389/fphys.2018.01229
   PubMed Web of Science ®Google Scholar
• Sutariya B, Jhonsa D, Saraf MN. TGF-β: the connecting link between nephropathy and fibrosis. Immunopharmacol Immunotoxicol. 2016;38(1):39–49. doi:10.3109/08923973.2015.1127382
   PubMed Web of Science ®Google Scholar
• Gifford CC, Tang J, Costello A, et al. Negative regulators of TGF-β1 signaling in renal fibrosis; pathological mechanisms and novel therapeutic opportunities. Clin Sci. 2021;135(2):275–303. doi:10.1042/CS20201213
   PubMed Web of Science ®Google Scholar
• Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425(6958):577–584.
   PubMed Web of Science ®Google Scholar
• Xu P, Liu J, Derynck R. Post-translational regulation of TGF-β receptor and Smad signaling. FEBS Lett. 2012;586(14):1871–1884. doi:10.1016/j.febslet.2012.05.010
   PubMed Web of Science ®Google Scholar
• Hata A, Chen Y-G. TGF-β signaling from receptors to Smads. Cold Spring Harb Perspect Biol. 2016;8(9). doi:10.1101/cshperspect.a022061
   PubMed Web of Science ®Google Scholar
• Wang H, Jiang Q, Zhang L. Baicalin protects against renal interstitial fibrosis in mice by inhibiting the TGF-β/Smad signalling pathway. Pharm Biol. 2022;60(1):1407–1416. doi:10.1080/13880209.2022.2097700
   PubMed Web of Science ®Google Scholar
• X-T L, Song J-W, Zhang -Z-Z, et al. Sirtuin 7 mitigates renal ferroptosis, fibrosis and injury in hypertensive mice by facilitating the KLF15/Nrf2 signaling. Free Radic Biol Med. 2022;193(Pt 1):459–473. doi:10.1016/j.freeradbiomed.2022.10.320
   PubMedGoogle Scholar
• Liu Y, Dong Z-J, Song J-W, et al. MicroRNA-122-5p promotes renal fibrosis and injury in spontaneously hypertensive rats by targeting FOXO3. Exp Cell Res. 2022;411(2):113017. doi:10.1016/j.yexcr.2022.113017
   PubMed Web of Science ®Google Scholar
• Lavoz C, Droguett A, Burgos ME, et al. Translational study of the Notch pathway in hypertensive nephropathy. Nefrologia. 2014;34(3):369–376. doi:10.3265/Nefrologia.pre2014.Jan.12436
   PubMed Web of Science ®Google Scholar
• Edeling M, Ragi G, Huang S, Pavenstädt H, Susztak K. Developmental signalling pathways in renal fibrosis: the roles of Notch, Wnt and Hedgehog. Nat Rev Nephrol. 2016;12(7):426–439. doi:10.1038/nrneph.2016.54
   PubMed Web of Science ®Google Scholar
• H-H H, Chen D-Q, Wang Y-N, et al. New insights into TGF-β/Smad signaling in tissue fibrosis. Chem Biol Interact. 2018;292:76–83. doi:10.1016/j.cbi.2018.07.008
   PubMed Web of Science ®Google Scholar
• Xiao J-H, Zhang J-H, Chen H-L, Feng X-L, Wang J-L. Inhibitory effects of isoliensinine on bleomycin-induced pulmonary fibrosis in mice. Planta Med. 2005;71(3):225–230.
   PubMed Web of Science ®Google Scholar